MARKET

LIXT

LIXT

Lixte
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.810
+0.210
+8.08%
Closed 16:19 05/17 EDT
OPEN
2.580
PREV CLOSE
2.600
HIGH
2.850
LOW
2.570
VOLUME
54.13K
TURNOVER
--
52 WEEK HIGH
7.86
52 WEEK LOW
2.360
MARKET CAP
188.40M
P/E (TTM)
-9.7131
1D
5D
1M
3M
1Y
5Y
Schedule For Benzinga's Global Small Cap Conference Thursday, May 13, 2021
Check out the full agenda via Benzinga's Events page: https://www.benzinga.com/events/small-cap/global/#agenda * the list below is limited to some of the publicly-traded companies that will be presenting
Check out the full agenda via Benzinga's Events page:  * the list below is limited to some of the publicly-traded companies that will be presenting · 4d ago
LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THE APPOINTMENT OF REGINA BROWN TO ITS BOARD OF DIRECTORS
EAST SETAUKET, NY, May 12, 2021 (GLOBE NEWSWIRE via COMTEX) -- EAST SETAUKET, NY, May 12, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc....
GlobeNewswire · 5d ago
10-Q: LIXTE BIOTECHNOLOGY HOLDINGS, INC.
(EDGAR Online via COMTEX) -- ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Forward-Looking Statements This...
Edgar Online - (EDG = 10Q, 10K) · 5d ago
Protein Phosphatase 2A Market Size 2021: Impact of Covid-19, Top Manufacturers, Regional Outlook, Competitive Strategies and Forecasts 2027
May 07, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." The Global "Protein Phosphatase 2A Market"...
The Express Wire · 05/07 06:35
Lixte Biotechnology to Present Key Advantages of Novel Cancer Drug Candidate LB-100 at the Sidoti Virtual Microcap Conference on May 20
EAST SETAUKET, NY, May 04, 2021 (GLOBE NEWSWIRE via COMTEX) -- Multiple pre-clinical studies indicate that Lixte's lead clinical drug candidate LB-100...
GlobeNewswire · 05/04 20:30
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Benzinga · 05/04 16:41
Lixte Biotechnology to Discuss Pipeline of Clinical Investigations for Four Cancer Targets at the Benzinga Global Small Cap Conference Being Held May 13-14
Lixte’s pipeline includes three clinical studies and one pharmacology study of lead drug candidate LB-100 EAST SETAUKET, NY, April 28, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company devel...
GlobeNewswire · 04/28 13:35
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers
Benzinga · 04/27 20:57
More
Forecast
No Data
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LIXT. Analyze the recent business situations of Lixte through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.79%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
President/Chief Executive Officer/Chief Scientific Officer/Director
John Kovach
Chief Financial Officer/Vice President
Robert Weingarten
Chief Administrative Officer
Eric Forman
Other
James Miser
Director
Stephen Forman
Director
Winson Ho
Director
Gil Schwartzberg
Director
Yun Yen
Independent Director
Regina Brown
Independent Director
Philip Palmedo
No Data
  • All
  • Financials
  • Insiders
More
About LIXT
Lixte Biotechnology Holdings, Inc. is a drug discovery company. The Company uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. It's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers, and includes two categories of compounds at various stages of pre-clinical and clinical development. It is developing two series of pharmacologically active drugs, the LB-100 series and the LB-200 series. The LB-100 series consists of novel structures, which may be useful in the treatment of not only several types of cancer but also vascular and metabolic diseases. The LB-200 series contains compounds which may be useful for the treatment of chronic hereditary diseases, such as Gaucher’s disease, in addition to cancer and neurodegenerative diseases.

Webull offers kinds of Lixte Biotechnology Holdings Inc stock information, including NASDAQ:LIXT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LIXT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LIXT stock methods without spending real money on the virtual paper trading platform.